SEC Stock Data Quick Answer EXAGEN INC. reported Total Revenue of $66.58 million for fiscal year 2025. EXAGEN INC. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $66.58M +19.7% 2024 $55.64M +5.9% 2023 $52.55M +15.3% 2022 $45.56M -5.7% 2021 $48.30M +15.1% 2020 $41.98M +3.9% 2019 $40.39M +24.5% 2018 $32.44M — Quarterly Total Revenue Quarter … Read more
Quick Answer EXAGEN INC. reported Total Revenue of $66.58 million for fiscal year 2025. EXAGEN INC. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $66.58M+19.7% $55.64M+5.9% $52.55M+15.3% $45.56M-5.7% $48.30M+15.1% $41.98M+3.9% Revenue (ASC 606) $66.58M+19.7% $55.64M+5.9% $52.55M+15.3% $45.56M-5.7% $48.30M+15.1% $41.98M+3.9% Net Income -$19.95M-32.0% -$15.12M+36.2% -$23.69M+50.0% -$47.39M-76.5% -$26.85M-60.9% -$16.69M-38.6% Diluted EPS … Read more
Quick Answer X4 Pharmaceuticals, Inc reported Shares Outstanding of 90.91 million shares for fiscal year 2025. X4 Pharmaceuticals, Inc Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 90.91M +1495.4% 2024 5.70M -96.6% 2023 167.43M +37.6% 2022 121.67M +332.6% 2021 28.13M +72.5% 2020 16.31M +1.1% 2019 16.13M +4486.6% 2018 351,652 -97.5% 2017 … Read more
Quick Answer X4 Pharmaceuticals, Inc reported Operating Income of -$86.88 million for fiscal year 2025. X4 Pharmaceuticals, Inc Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$86.88M -138.7% 2024 -$36.40M +66.1% 2023 -$107.52M -22.8% 2022 -$87.57M -2.9% 2021 -$85.11M -42.1% 2020 -$59.87M -15.8% 2019 -$51.70M -77.8% 2018 -$29.09M -30.7% 2017 -$22.25M … Read more
Quick Answer X4 Pharmaceuticals, Inc reported R&D Expense of $72.72 million for fiscal year 2025. X4 Pharmaceuticals, Inc R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $72.72M -10.9% 2024 $81.64M +13.4% 2023 $72.02M +17.9% 2022 $61.06M +20.6% 2021 $50.65M +20.8% 2020 $41.93M +39.0% 2019 $30.16M +48.3% 2018 $20.35M +19.2% 2017 $17.07M … Read more
Quick Answer X4 Pharmaceuticals, Inc reported Stockholders Equity of $186.29 million for fiscal year 2025. X4 Pharmaceuticals, Inc Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $186.29M +741.1% 2024 $22.15M -56.7% 2023 $51.10M -31.0% 2022 $74.05M +15.0% 2021 $64.41M -11.5% 2020 $72.80M -43.7% 2019 $129.22M +267.6% 2018 -$77.09M -73.1% 2017 -$44.55M … Read more
Quick Answer X4 Pharmaceuticals, Inc reported Cash and Equivalents of $217.05 million for fiscal year 2025. X4 Pharmaceuticals, Inc Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $217.05M +289.7% 2024 $55.70M -43.9% 2023 $99.22M -18.5% 2022 $121.72M +48.8% 2021 $81.79M +3.9% 2020 $78.71M -37.6% 2019 $126.18M +1451.3% 2018 $8.13M … Read more
Quick Answer X4 Pharmaceuticals, Inc reported Total Assets of $290.46 million for fiscal year 2025. X4 Pharmaceuticals, Inc Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $290.46M +98.3% 2024 $146.45M -0.6% 2023 $147.26M -5.4% 2022 $155.59M +32.8% 2021 $117.18M -4.6% 2020 $122.87M -23.5% 2019 $160.70M +1516.0% 2018 $9.94M -87.8% 2017 $81.25M … Read more
Quick Answer X4 Pharmaceuticals, Inc reported Diluted EPS of $1.87 per share (loss) for fiscal year 2025. X4 Pharmaceuticals, Inc Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$1.87 +66.5% 2024 -$5.59 +67.3% 2023 -$17.07 -1023.0% 2022 -$1.52 +61.9% 2021 -$3.99 -29.1% 2020 -$3.09 — Quarterly Diluted EPS Quarter Ending Diluted … Read more
Quick Answer X4 Pharmaceuticals, Inc reported Net Income of -$79.20 million for fiscal year 2025. X4 Pharmaceuticals, Inc Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$79.20M -111.5% 2024 -$37.45M +63.0% 2023 -$101.17M -7.8% 2022 -$93.87M -5.8% 2021 -$88.70M -42.8% 2020 -$62.13M -17.7% 2019 -$52.81M -58.7% 2018 -$33.28M -51.3% 2017 -$21.99M … Read more